255P First-in-human, phase I, open-label, multicentre study of INCA32459, a LAG-3 and PD-1 bispecific antibody in patients with select advanced malignancies (AM)
vaccination timing relative to SoC is likely to be important and cannot necessarily be predicted preclinically.
Authors
- G.A. De Velasco Oria
- S.A. Piha-Paul
- J.F. Baurain
- M. Dudzisz-Sledz
- Y. Fang
- H. Prenen
- L.A. D'Hondt
- G. Alonso
- S. Rottey
- Z. Dong
- J. Fuentes Antras
- I. Moreno Candilejo
- O. Hamid
- J. Martin-Liberal
- R. Schaub
- N. Bourayou
- L. Cheng
Institutions
- Cliniques Universitaires Saint-Luc (BE)
- The University of Texas MD Anderson Cancer Center (US)
- Universitair Ziekenhuis Leuven (BE)
- Research Institute Hospital 12 de Octubre (ES)
- CHU Dinant Godinne UCL Namur (BE)
- Centro Oncológico de Galicia (ES)
- Angeles Clinic and Research Institute (US)
- Ajuntament de L’Hospitalet (ES)
- Institut Català d'Oncologia (ES)
- Hospital Universitario Quirónsalud Madrid (ES)
- Universitair Ziekenhuis Brussel (BE)
- FC Barcelona (ES)
- International Drug Development (FR)
- Incyte (United States) (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2025.101454
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research UK
- Genentech